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Revision rates after total knee replacement (TKR) are about 
9.5% in Germany and about 8.4% in the USA for the year 
2011 (Wengler et al. 2014). The pathogenesis of implant fail-
ure is multifactorial (Sharkey et al. 2002, Bourne et al. 2010), 
and adverse reactions to metal ions released from arthroplasty 
represent one such factor. Both unspecific (“innate”) immune 
reactions and specific T lymphocytic sensitization with subse-
quent hypersensitivity mechanisms may contribute to arthro-
plasty intolerance reactions in patients (Mahendra et al. 2009, 
Reito et al. 2016, Hallab et al. 2017).
The clinical spectrum encompasses both local and systemic 
effects, being often unspecific like: pain, swelling, effusion, 
reduced range of motion, impaired wound healing, eczema. 
Diagnostic findings include osteolysis, lymphocyte-dominated 
peri-implant inflammation, and in extreme situations soft 
tissue necrosis or pseudotumor formation. In 2017 Hallab et al. 
framed the statement “a consensus of studies agree the domi-
nant form of this response is due to innate reactivity to implant 
debris danger signaling” (Hallab et al. 2017). Thus, the corre-
sponding release of cytokines and chemokines might open the 
way to implant failure. Examples are: chemokines like IL-8, 
CXCL10, or monocyte chemotactic protein-1 (Lawrence et 
al. 2014), danger signaling associated inflammasome pathway 
with IL-1ß/IL-18 formation (Yang et al. 2015) or TIRAP/Mal 
mediated particle-induced osteolysis (Bechtel et al. 2016). 
Correspondingly, various approaches have been discussed 
to diminish the metal ion exposure in arthroplasty patients, 
such as reducing wear by modifying modularity or surface 
modification (Bolognesi et al. 2015, Morlock 2015, Thomas et 
al. 2015). It might be speculated that the mostly inflammatory 
pathologic reactions to metal ions and debris represent stages 
of “broken tolerance” of the implant-exposed organism. How-
ever, the underlying mechanisms leading to immune homeo-
Background and purpose — Metal sensitivity might 
provoke complications after arthroplasty. Correspondingly, 
coated “hypoallergenic” implants are of interest but long-
term follow-up data are missing. Thus, we assessed immu-
nological and clinical parameters in such patients.
Patients and methods — 5 years’ follow-up data were 
obtained from 3 centers, which used either a standard total 
knee replacement (TKR) or the identical implant with mul-
tilayer surface zirconium nitride based coating. Of the 196 
patients (mean age 68 years (44–84), 110 females) 97 had 
arthroplasty with a coated surface, and 99 were treated by 
a standard TKR of the same type. Investigations were Knee 
Society Score (KSS), Knee injury and Osteoarthritis Out-
come Score (KOOS), radiographic analysis, and cytokine 
measurement in peripheral blood. Pro- and anti-inflamma-
tory cytokines were evaluated by cytometric beads assay and 
RT-PCR.
Results — Survival rate (Kaplan–Meier) was 98% 
for coated and 97% for uncoated implants after 5 years. 
Mechanical axis and KSS pain score (42 vs. 41  (0–50)) were 
comparable. Most serum cytokine levels were comparable, 
but mean interleukin-8 and interleukin-10 levels were higher 
in the group with an uncoated implant. IL-8: 37 (SD 7.5) pg/
mL vs. 1.1 (SD 4.3) (p < 0.001); IL-10: 3.6 (SD 2.5) vs. 0.3 
(SD 1.8) pg/mL (p < 0.001).
Interpretation — There was similar clinical outcome 
5 years after standard and surface-coated TKR. In periph-
eral blood there was an increased pro-inflammatory status, 
i.e., significant elevation of IL-8 and the anti-inflammatory 
IL-10, after standard uncoated prosthesis. Any long-term 
effects of these cytokine changes are unknown.
Acta Orthopaedica 2018; 89 (6): 646–651 647
also recognizable by this approach. 
Patients and methods
Patients and controls
All 322 patients who received a TKR (e.motion UC, Aesculap 
AG, Tuttlingen, Germany) in 2007 were invited for mid-term 
follow-up (around 5 years). Of these, 41 patients were lost to 
follow-up. For 78 patients, who were not willing or able to 
participate in the follow-up, at least information on prosthesis 
status could be obtained and in 7 patients 1 or more implant 
components had been exchanged. 196 patients (mean age 68 
years [44–84], 110 females) with primary knee arthroplasty 
took part in the study (Table). The follow-up examinations 
were done in 3 centers:
(a) Klinikum Memmingen (Germany, center 1); here all 
patients received exclusively the surface-coated variant of the 
knee implant.
(b) Lukas Hospital Bünde (Germany, center 2) and Hospi-
tal Oberwallis Brig (Switzerland, center 3); here patients rou-
tinely received the uncoated variant of the knee implant.
In centers 2 and 3, if patients had a history of metal allergy 
they received the surface-coated implant. These few patients 
are not included in this evaluation. All standard knee implants 
used were CoCr alloys and were cemented. Only patients from 
center 3 had received retropatellar resurfacing, but no differ-
ence in cytokine levels was found between the two centers (2 
and 3) with uncoated implants.
The follow-up assessment encompassed clinical, radiologi-
cal, and immunological examination. Analysis of blood sam-
ples was done at the Department of Dermatology and Aller-
gology, Ludwig-Maximilians-University (LMU) Munich. The 
Table gives the patients’ characteristics. 
In addition to the arthroplasty patients, 40 individuals with-
out a metal implant volunteered as blood donors for cytokine 
control assessment: 20 healthy individuals (median age 61 
years [52–63], 14 females; 3 with a history of metal allergy) 
without a metal implant; 20 individuals with knee osteo-
arthritis prior to primary arthroplasty (median age 60 years 
[46–84], 17 females; 14 with a history of metal allergy). The 
20 individuals prior to arthroplasty were patients presented 
by their orthopedic surgeons to the Department of Dermatol-
ogy and Allergology of LMU for allergy diagnostics. Thus in 
this group patients with an allergy background are overrepre-
sented. However, we thought that pre-existing “allergy status” 
would not alter preoperative blood cytokine levels.
Clinical and radiological assessments
A detailed physical examination was done. In addition, func-
tional and symptom assessment was performed by Knee Soci-
ety Score (KSS) and Knee injury and Osteoarthritis Outcome 
Score (KOOS). Radiological evaluation was done using stan-
dard weight-bearing knee radiographs in two planes and in 
load-bearing leg axis to evaluate prosthesis positioning and 
presence of radiolucencies. 
Analysis of blood cytokine levels and expression
From each patient 2 blood samples were obtained.
First sample — After blood drawing, serum was obtained 
from this sample by centrifugation and immediately frozen. 
190 cryopreserved serum samples (98 patients with uncoated, 
92 patients with coated arthroplasty) could be analyzed. The 
blinded samples were assessed for the presence and concen-
tration of 10 cytokines by a multiplex cytometric bead assay 
(CBA; BD Biosciences, Heidelberg, Germany) via flow 
cytometry using a FACS canto (BD Biosciences, Heidelberg, 
Germany). The panel of cytokines included—with the restric-
tion of sometimes overlapping functions—inflammatory 
(IL-4, IL-5, IL-6, IL-17A, IL-1ß, IFNγ, TNFa), chemoattrac-
tant (IL-8, CXCL10), and immune-regulating (IL-10) factors. 
The respective detection limits were < 0.5 pg/mL.
Characteristics of the 196 patients with primary TKR and of the 40 individuals with-
out metal implant
    Group IV
 Group I Group II Group III healthy
 uncoated a coated b preoperative c controls d
Patients 99 97 20 20
Sex (female/male) 54/45 56/41  17/3 14/6
Age median (years) 67 (44–84) 70 (48–82) 60 (46–84) 61 (52–63)
Smoker (formely smokers)   5 (11) 10 (19)   2   2
History of skin metal allergy   0   6 14   3
Atopy e 11   4 12   3
a Uncoated = primary knee arthroplasty with e.motion.
b Coated = primary knee arthroplasty with multilayer coated, i.e., AS e.motion. 
c Gonarthrosis patients, prior to knee arthroplasty (at present no metal implant)
d Healthy patients without metal implant.
e Atopy = history of hay fever and/or allergic asthma and/or atopic dermatitis.
stasis are also not well understood in patients 
with symptom-free arthroplasty. 
We compared 2 groups of TKR patients at 
5-year follow-up who had had the identical 
type of prosthesis with one exception: In half of 
the patients a variant was implanted with mul-
tilayer Advanced Surface (AS) coating (zirco-
nium nitride (ZrN)) to reduce metal ion release. 
First, we assessed the clinical performance 
of the 2 variants of TKR in these patients. 
Second, we investigated immune reactivity to 
TKR with a focus on the systemic response, 
i.e., the response pattern of selected cytokines 
and chemokines in peripheral blood. The latter 
was done because, in contrast to in vitro stud-
ies often using cell lines, such an approach is 
rarely performed. We hypothesized that a local 
yet “subclinical” inflammatory state might be 
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Second sample — A peripheral blood sample with EDTA 
was stabilized with RNAlater (Ambion, Carlsbad, USA) and 
cryopreserved. Then RNA was isolated with the RiboPure 
Blood Kit (Ambion, Carlsbad, USA). After reverse transcrip-
tion into cDNA (Transcriptor First strand cDNA Synthesis 
Kit, Roche, Mannheim, Germany) gene expression of 5 dif-
ferent genes (IFNγ, Foxp3, IL-10, IL-8, CASP1) was analyzed 
by semiquantitative realtime PCR in a LightCycler 1.5.
Statistics
The statistical packages SPSS (Version 19.0; SPSS Inc, Chi-
cago, IL, USA) and SAS (Version 9.4; SAS Institute, Cary, 
NC, USA) were used. Differences in the blood cytokine levels 
were assessed using Student’s t-test. Prosthesis survival was 
calculated by Kaplan–Meier analysis.
Ethics, funding, and potential conflicts of interest
The study was approved by the local ethics committee 
(approval number 186-12). Patient examination and blood 
sampling was done after obtaining informed consent. Fund-
ing was by a research grant from Aesculap AG. There was no 
further conflict of interest.
Results
Orthopedic and radiologic outcomes 
The average time of follow-up in the 196 arthroplasty patients 
was 5.7 years (54–77 months). The mean BMI was 28 (20–44) 
and was comparable between the groups. The KSS were simi-
lar between the centers and groups: Center 1 (patients with 
surface-coated TKR): mean 84 (SD 15). Center 2 (patients 
with uncoated TKR): mean 82 (SD 19). Center 3 (patients 
with uncoated TKR): mean 85 (SD 15). 
Radiolucent lines were investigated by plain radiographs. 
No complete loosening was observed. The revision free 
implant survival rates after 5 years (Kaplan–Meier) were com-
parable with 98% for coated and 97% for uncoated implants. 
Cytokine levels and expression in peripheral blood
Blood samples of 190 patients could be evaluated. Marked 
differences were found for 3 of the 10 cytokines. There was 
a clear-cut difference between patients with uncoated and 
coated arthroplasty in circulating level of: (i) IL-8 (37 pg/mL 
[SD 5.6] vs. 1.2 pg/mL [SD 2.1]; p < 0.001); (ii) IL-10 (3.6 
pg/mL [SD 8.9] vs. 0.25 pg/mL [SD 0.5]; p < 0.001); (iii) 
and to a lesser extent IL-6 (2.9 pg/mL [SD 2.0] vs. 2.3 pg/mL 
[SD 3.4]; p < 0.05). Levels of CXCL10 did not differ statisti-
cally significantly (64.9 pg/mL, SD 39.0 vs. 55.6 pg/mL, SD 
29.9). The osteoarthritis control patients (prior to arthroplasty) 
also showed a less pronounced IL-8 and CXCL-10 elevation 
as compared with the healthy controls. With regard to IL-8 
and IL-10, the serum cytokine levels of the healthy controls 
were similar to those of the patients with a coated arthroplasty. 
When comparing results of patients with allergy background 
(here mostly “atopy”) with those without such background, no 
major difference was found in the different groups. The data 
are summarized in Figure 1.
The statistically significant difference of the IL-8 content in 
the serum samples of arthroplasty patients was paralleled by 
a significant difference in the IL-8 expression on RNA level 
(uncoated: 0.18 [SD 0.02] vs. coated: 0.09 [SD 0.007]). RNA 
analysis was also done for Foxp3 and IL-10 with the intention 
to assess regulatory cell marker, for a caspase (casp1) respon-
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Figure 2. Relative expression levels of mRNA 
for IL-10 and IL-8 in peripheral blood of patients 
with the uncoated (n = 98) and coated (n = 92) 
TKR (e.motion/e.motion-AS). c p < 0.001; stan-
dard deviation is given. NS: not significant.
Figure 1. (left panel) Serum cytokine levels in patients with the uncoated (n = 98) and coated 
(n = 92) TKR (e.motion/e.motion-AS). (right panel) Serum cytokine levels in 20 patients prior 
to primary arthroplasty (“preoperative”) and 20 healthy individuals without implant (“con-
trols”). The cytokines IL8, IL-6, the immunoregulatory IL-10, and the T-cell chemoattractant 
CXCL10 were assessed. Concentrations are given in pg/mL. b p < 0.01; c p < 0.001; standard 
deviation is given. 
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sible for cleaving pro IL-1ß into its active form and for IFNγ. 
Expression of all 4 of these  was, however, similar in the 2 
patient groups. The results of IL-8 and IL-10 expression are 
shown in Figure 2.
Discussion
It is believed that after wound healing and tissue regenera-
tion most arthroplasty patients adapt to the implant and regain 
quality of life. However, tissue homeostasis around the “for-
eign body” may be disturbed by inflammatory mediator 
response to wear and metal ions. Discussion was triggered by 
some patients developing extreme adverse reactions to metal-
on-metal hip arthroplasty, i.e., pseudotumor formation (Hutt 
et al. 2016). Jämsen et al. (2017) described the correlations 
between macrophage polarizing cytokines, osteoclast activity, 
and toll-like receptors—particularly TLR4 in tissue around 
aseptically loosened hip implants. Among other things, they 
reported that IL-8 expression correlates with early revision 
time. Apart from potential toxic or unspecific immunostimu-
latory mechanisms, metal allergy could also play a role since 
enhanced metal sensitivity has been found in patients with 
failed arthroplasty (Hallab et al. 2001, Thomas et al. 2009, 
Granchi et al. 2012). Thus, use of alternative materials or sur-
face-coated CoCrMo alloys could be an alternative for metal-
sensitive patients (Bader et al. 2008). In our study we describe 
comparable good clinical 5-year results in patients with the 
same CoCrMo-based TKR in uncoated and surface-coated 
versions. The second major conclusion of our study is that 
patients with uncoated, well-performing TKR nevertheless 
present with a subclinical proinflammatory cytokine pattern in 
the peripheral blood. Unexpectedly, we found that serum IL-8 
was substantially elevated in standard uncoated TKR patients. 
Since in center 1 the surface-coated variant of TKR was used 
in all patients, the patient series consisted of 6/97 with and 
91/97 without known metal allergy. This approach avoids a 
selection bias regarding metal-allergic patients. The clinical 
performance reflected by the KSS score was almost identi-
cal. This is in line with the Kaplan–Meier implant survival 
rate of 98% (coated) and 97% (uncoated). These numbers are 
in accordance with published data on 5-year survival rates of 
TKR ranging between 88 and 98% (Lee et al. 2013). 
The rationale for determination of selected cytokines and 
chemokines in peripheral blood was: first, to avoid joint aspi-
rates in symptom-free patients and second, systemic cytokine 
pattern in peripheral blood is described to reflect a variety 
of local tissue conditions (for example rheumatoid arthritis, 
malignant tumor, hepatic or lung inflammatory disease) (Fang 
et al. 2016, Lin et al. 2016, Matz et al. 2016, Tan et al. 2017).
We selected an array of partly innate proinflammatory 
mediators (IL-1ß, IL-4, IL-5, IL-6, IL-8), the specific T-cell 
chemoattractant CXCL10 and the counterregulatory immune 
“dampening” IL-10. Also, when comparing with the “normal” 
situation, i.e., osteoarthritis patients prior to knee arthroplasty 
and healthy individuals without osteoarthritis and without 
implant, a significantly higher blood level of IL-8 was found 
in patients with uncoated CoCrMo-based TKR. Despite an 
allergy background being overrepresented in the 20 preop-
erative controls, this did not influence the “unspecific blood 
cytokine profile”. In addition, molecular analysis of periph-
eral blood cells showed enhanced expression of IL-8 in the 
patients with uncoated TKR. When considering conditions 
with potential immune activation/production of systemic pro-
inflammatory mediators, elevated IL-8 levels are typically 
found in various settings: exercise stimulates increases in the 
circulating concentrations of several cytokines, namely IL-8 
(Peake et al. 2015); in peripheral arterial disease acute phase 
proteins, matrix metalloproteases, and cytokines—in particu-
lar IL-8—are considered as potential biomarkers of patho-
gen-related inflammation (Signorelli et al. 2014); the degree 
of elevated serum IL-8 is related to the extent of potential 
inflammation and fibrosis in chronic liver disease (Nobili et 
al. 2004); elevated serum IL-8 levels are found for several 
types of cancer and are discussed as a prognostic marker 
for malignant disease (Palena et al. 2012, Jin et al. 2014). 
Already in 2005 Tanaka et al. had reported two observations: 
serum and synovial fluid IL-8 levels were significantly cor-
related in hip arthroplasty patients—and elevated IL-8 levels 
correlated with aseptic loosening of hip arthroplasty (Tanaka 
et al. 2005). 12 years later, in 2017 Jämsen et al. in retrieval 
tissue samples not only observed the “protective” IL-4 polar-
ized M2 macrophage type and the IFNγ governed M1 mac-
rophage type adding to aseptic loosening, but also found that 
“IL-8 expression correlates with early revision time” (Jämsen 
et al. 2017). 
Metal ions, in particular cobalt, greatly enhance in vitro 
IL-8 production by various cell types (Ninomiya et al. 2013 , 
Lawrence et al. 2014). Recent investigations have shown that 
cobalt and nickel induce such IL-8 expression via TLR4 acti-
vation (Anjum et al. 2016, Lin et al. 2016). In addition, as 
reported by Lawrence et al. (2014), cobalt ions promote the 
expression of CXCL10, a T-lymphocyte chemokine. Similarly 
to IL-6 (Wang et al. 2014, Ettinger et al. 2015) as contribu-
tor to autoimmune and inflammatory diseases, the chemokine 
IL-8 has multiple proinflammatory effects. As an intravascular 
danger signal it enables trafficking of leukocytes to sites of 
tissue injury (by chemotaxis and expression of vascular adhe-
sion molecules), it promotes neovascularization, it enables 
epithelial–mesenchymal transition (both in wound healing/
tissue regeneration and fibrosis/cancer progression) and it pro-
longs ongoing inflammation. With regard to prolonged peri-
implant inflammatory response, Anjum et al. (2016) presented 
an interesting working model. Cobalt ions released from 
arthroplasty activate TLR4 on immune cells and endothelial 
cells, resulting in cytokine and chemokine (including IL-8) 
release that leads among others to inflammatory cell recruit-
ment from the circulation. 
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Were our patients with “standard”, i.e., uncoated, TKR and 
high IL-8 levels at risk of earlier revision? When planning the 
study—yet unaware of such results—we had wondered if also 
some specific, i.e., T-cell related, marker or cytokines reflect-
ing regulatory mechanism were demonstrable in our patients. 
For the latter aspects we assessed IL-10 for the following rea-
sons: Martire-Greco et al. (2013) had reported that addition 
of IL-10 reduced LPS-induced TNFa- and IL-8 secretion of 
human neutrophils in vitro; IL-10 was found to reflect a potent 
anti-inflammatory, immune-dampening response for example 
in pregnancy allowing “fetal tolerance” (Santner-Nanan et al. 
2013), in successful immunotherapy with pollen allergens 
(Jutel and Akdis 2011) or symptom-free metal (titanium) 
dental implant patients (Thomas et al. 2013). Apart from its 
tolerogenic role IL-10 can also play a role in immune-mediated 
diseases by promoting autoantibody production and cytotoxic 
T-cell responses (Geginat et al. 2016). Even if we tend to con-
sider the here observed IL-10 production as immunoregula-
tory, such a pivotal role of IL-10 together with enhanced IL-8 
production needs attention in future investigations. Cassuto et 
al. (2017) have recently reported their results of repeated mea-
suring of plasma biomarkers in hip arthroplasty over a period 
of almost 2 decades. Among their findings, there was a striking 
peak of IL-8 around 5–6 years post-surgery and a late rise of 
RANKL. In this study the focus was set on bone remodeling/
healing phenomena. Nevertheless such a late proinflammatory 
mediator peak accords with our findings. Unfortunately IL-10 
levels were not assessed by Cassuto et al. (2017). 
Since CXCL10 is described as a chemoattractant for the 
recruitment of activated T-cells (Wang et al. 2016), i.e., thus 
prolonging or increasing adaptive immune response, we 
assessed its serum levels as well. The 2 arthroplasty patient 
groups had more elevated levels with the highest, but sta-
tistically non-significant, increase in uncoated arthroplasty. 
Expression of Foxp3 as a marker of regulatory T-cells could 
again be found in both patient groups, with not significantly 
higher values in the uncoated TKR group. 
Immune reactivity to implanted metal arthroplasty is an area 
of growing research intensity. At the same time the under-
standing of immunological responses to it and of cytokine 
homeostasis in such patients still remains incomplete. Our 
study, to our knowledge, is the first comparative analysis of 
serum cytokine responses and clinical performance in patients 
with standard and surface-coated TKR. The observed differ-
ences, i.e., the proinflammatory yet clinically inapparent and 
controlled condition in the standard TKR patient, should trig-
ger further work to identify additional factors contributing to 
implant failure in given patients. Subsequent studies should 
include blood sampling at more time points and also follow-
up study examinations with the 10- and 15-year results should 
be planned.
In summary, we could observe differences in cytokine pat-
terns between patients with coated and uncoated knee joint 
implants but with similar clinical outcomes at the 5-year fol-
low-up. Identifying the complex interplay of individual “bio-
mediators” may add to the understanding of why implants 
might fail. Thus, the long-term cumulative effect of those 
cytokine changes should be a matter for further research.
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